Lead Sponsor

Sunshine Lake Pharma Co., Ltd.

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Yes

•1. male or female, age 18 to 70 years of age, inclusive;
•2. must have a calculated body mass index (BMI) from 18 to 28 kg/m2 at study screening;
•3. Glomerular filtration rate must be \< 15 mL/min /1.73 m2 for End-stage renal disease without hemodialysis group, and ≥ 90 mL/min for Normal Renal Function group(using MDRD method);
•4. matched for age (±5 years) ,gender and BMI(±15%) with a subject in the End-stage renal disease without hemodialysis group;

•1. allergies constitution ( multiple drug and food allergies);
•2. Use of \>5 cigarettes per day during the past 3 months;
•3. A positive test results for HbsAg, Hepatitis C antibody, HIV-1 antibody, or Treponema pallidum antibody；
•4. History of alcohol abuse；
•5. Donation or loss of blood over 400 mL within 3 months prior to the first dose of study drug；
•6. Subjects deemed unsuitable by the investigator for any other reason.

Related studies

NCT07348237 · Chronic Kidney Failure, End-Stage Renal Disease, and more

NCT07426380 · Kidney Disease, Renal Insufficiency Chronic, and more

NCT07154901 · Renal Impairment

NCT07551570 · Renal Impairment

NCT07165015 · Renal Impairment, Healthy, and more

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD